MARKET

RGNX

RGNX

Regenxbio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

41.43
+1.35
+3.36%
Opening 12:54 02/24 EST
OPEN
40.05
PREV CLOSE
40.08
HIGH
42.00
LOW
39.95
VOLUME
106.03K
TURNOVER
--
52 WEEK HIGH
51.14
52 WEEK LOW
20.03
MARKET CAP
1.73B
P/E (TTM)
-16.7293
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights
REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, March 1, 2021, at 4:30 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2020, and recent operational highlights.
PR Newswire · 1d ago
Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
Zacks.com · 02/17 17:32
Regenxbio Gene Therapy Shows Treatment Benefit In Wet AMD Study
Benzinga · 02/16 14:09
Regenxbio's RGX-314 shows potential as a one-time treatment option in wet AMD
Regenxbio (RGNX) reports additional positive interim data from Cohorts 4 and 5 of its RGX-314 Phase I/IIa trial for the treatment of wet age-related macular degeneration (wet AMD), and Cohort 3
Seekingalpha · 02/16 12:36
REGENXBIO Announces Additional Interim Phase I/IIa And Long-Term Follow-Up Data Of RGX-314 For Wet AMD
RGX-314 using subretinal delivery continues to be generally well-tolerated at all dose levels Positive interim update from Cohorts 4 and 5 at 1.5 years after RGX-314 administration Durable treatment effect
Benzinga · 02/16 12:11
REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD
ROCKVILLE, Md., Feb. 16, 2021 /PRNewswire via COMTEX/ -- ROCKVILLE, Md., Feb. 16, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) reported at the...
PR Newswire - PRF · 02/16 12:05
Regenxbio Unveils Data From Trial of Potential Treatment for Eye Disease
MT Newswires · 02/16 09:05
15 Best Small-Cap Healthcare Stocks to Buy
In this article, we present the 15 Best Small-Cap Healthcare Stocks to Buy. If you’re in a hurry, click to skip ahead and see the 5 Best Small-Cap Healthcare Stocks to Buy. The term small cap can be used to define established companies with a small market ...
Insider Monkey · 02/14 18:32
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RGNX. Analyze the recent business situations of Regenxbio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RGNX stock price target is 63.89 with a high estimate of 100.00 and a low estimate of 40.00.
EPS
Institutional Holdings
Institutions: 285
Institutional Holdings: 28.80M
% Owned: 69.12%
Shares Outstanding: 41.66M
TypeInstitutionsShares
Increased
49
2.07M
New
55
-348.54K
Decreased
60
2.85M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.65%
Pharmaceuticals & Medical Research
+1.37%
Key Executives
Chairman/Director
Allan Fox
President/Chief Executive Officer/Executive Director
Kenneth Mills
Chief Financial Officer/Senior Vice President
Vittal Vasista
Senior Vice President/Chief Technology Officer
Curran Simpson
Senior Vice President/Chief Scientific Officer
Olivier Danos
Senior Vice President
Steve Pakola
Lead Director/Independent Director
A. N. Karabelas
Independent Director
Daniel Abdun-Nabi
Independent Director
Luke Beshar
Independent Director
Alexandra Glucksmann
Independent Director
David Stump
Independent Director
A.N. Karabelas
Independent Director
Daniel Tasse
  • Dividends
  • Splits
  • Insider Activity
No Data
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.

Webull offers kinds of Regenxbio Inc stock information, including NASDAQ:RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.